Core Viewpoint - Heng Rui Medicine announced the approval of clinical trial notifications for three drug candidates, indicating a significant step in their oncology pipeline [1] Group 1: Clinical Trials - The company’s subsidiaries received approval from the National Medical Products Administration to conduct clinical trials for SHR-A2102, Abediteranib injection, and SHR-1802 [1] - The trials will focus on the safety, tolerability, and efficacy of SHR-A2102 in combination with Abediteranib and SHR-1802 in patients with advanced solid tumors [1] Group 2: Drug Candidates - SHR-A2102 is a company-developed antibody-drug conjugate (ADC) targeting Nectin-4, with a payload of topoisomerase I inhibitor [1] - SHR-1802 is a humanized monoclonal antibody designed to activate and promote anti-tumor T cell responses [1] - Abediteranib injection is a humanized anti-PD-L1 monoclonal antibody that blocks the PD-1/PD-L1 pathway, reactivating the immune system's anti-tumor activity [1]